Evidence map›Paper›PMID 33525403›Full record

ArticleInternational journal of molecular sciences2021

Anti-Inflammatory Effects of Ellagic Acid on Keratinocytes via MAPK and STAT Pathways.

Tae-Young Gil, Chul-Hee Hong, Hyo-Jin An

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 54 citations in OpenAlex.

  1. Antioxidant and Anti-Aging Activity ofMolecules (Basel, Switzerland) · 2026
    Article
  2. Exploring the Anti-Inflammatory Effects ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Therapeutic Potential ofAntioxidants (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Frontiers in pharmacology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Phytotherapeutic potential ofIn silico pharmacology · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Life (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tae-Young GilDepartment of Pharmacology, College of Korean Medicine, Sangji University, Wonju-si 26339, Gangwon-do, Korea.
Chul-Hee HongDepartment of Korean Meidicne Ophthalmology & Otolaryngology & Dermatology, College of Korean Medicine, Sangji University, Wonju-si 26339, Gangwon-do, Korea.
Hyo-Jin AnDepartment of Pharmacology, College of Korean Medicine, Sangji University, Wonju-si 26339, Gangwon-do, Korea.
Sangji University · KR

Funding

National Research Foundation of Korea NRF-2018R1D1A1B07044794
6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by an impaired skin barrier and intense itchiness, which decreases the individual's quality of life. No fully effective therapeutic agents have prevailed for AD due to an insufficient grasp of the complex etiology. Ellagic acid (EA), a natural compound, has anti-inflammatory properties in chronic diseases. The effects of EA on AD have not yet been explored. The present study investigated the effects of EA on TNF-α/IFN-γ-stimulated HaCaT keratinocytes and house dust mite-induced AD-like skin lesions in NC/Nga mice. Treatment with EA suppressed inflammatory responses in keratinocytes by regulating critical inflammatory signaling pathways, such as mitogen-activated protein kinases and signal transducers and activators of transcription. In vivo studies using a DfE-induced AD mouse model showed the effects of EA administration through ameliorated skin lesions via decremented histological inflammatory reactions. These results suggest that EA could be a potential therapeutic alternative for the treatment of AD by inhibiting inflammatory signaling pathways.

Indexed as

AnimalsAntigens, DermatophagoidesAnti-Inflammatory AgentsChemokine CCL17Chemokine CCL22Chemokine CCL5Complex MixturesCytokinesDermatitis, AtopicDermatophagoides farinaeDisease Models, AnimalEllagic AcidFemaleGene Expression RegulationHaCaT CellsHumansAntigens, DermatophagoidesAnti-Inflammatory AgentsCcl17 protein, mouseCcl22 protein, mouseCcl5 protein, mouseChemokine CCL17Chemokine CCL22Chemokine CCL5Complex MixturesCytokinesEllagic AcidInterferon-gammaMitogen-Activated Protein KinasesStat1 protein, mouseSTAT1 Transcription FactorStat3 protein, mouseSTAT3 Transcription FactorThymic Stromal LymphopoietinTumor Necrosis Factor-alphaatopic dermatitischronic diseaseellagic acidinflammationMAPKsSTATs

Identifiers

PMID33525403
PMCPMC7865693
OpenAlexW3121942860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.